Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of TPF Induction Chemotherapy for Borderline-resectable Esophageal Squamous Cell Carcinoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients should be voluntary to the trial and provide with signed informed consent.~2. Male or female patients, age:18-70 years old~3. Confirmed by histology of thoracic esophageal squamous cell carcinoma without metastasis and diagnosed as boundary resectable by Multidisciplinary consultation, including cT4 and/or bulky lymphadenopathy that may invade nearby organs(such as the great vessels, trachea and heart, etc.)~4. Measurable or unmeasurable lesions according the RECIST 1.1 criteria.~5. No previous chemotherapy or radiotherapy.~6. Life expectancy ≥ 3 months.~7. ECOG PS 0-1.~8. Blood routine within 7 days：Hb ≥9g/L，NE ≥1.5×109/L，PLT ≥100×109/L；~9. Hepatic and renal function：TB \<1.5 UNL， Cr\< 1.5× UNL， AST / ALT \< 2.5× UNL， ALP \< 5.0 × UNL。~10. No severe complications such as active digestive tract hemorrhage, perforation, jaundice, gastrointestinal obstruction, non-cancerous fever \> 38 ℃~11. Fertile patients should take effective contraceptive measures.~12. Patients should have good compliance and cooperate with the evaluation of efficacy and adverse events and follow-ups according to the research plan.~Exclusion Criteria:~1. Cervical esophageal carcinoma.~2. Known severe hypersensitivity to drugs in the regimen.~3. Patient has a concurrent malignancy or has a malignancy within 5 years of study enrollment(with the exception of nonmelanoma skin cancer or cervical carcinoma in situ).~4. Evidence of serious heart disease, including recorded history of congestive heart-failure, uncontrolled serious arrhythmia, angina that needs treatment of drugs, clinical diagnosed cardiac valve disease, history of serious myocardial infarction and intractable hypertension.~5. Evidence of chronic diarrhea(≥4 times/day) or renal dysfunction.~6. Evidence of active infection or active epidemic disease.~7. Psychiatric illness that would prevent the patient from giving informed consent~8. Pregnant or lactating women.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Paclitaxel+Cisplatin+5fluorouracil (Type: EXPERIMENTAL): Patients will receive the following chemotherapy: Paclitaxel 135mg/m2 IV over 3 hours on Day 1; Cisplatin 75mg/m2 IV over 1 hours on Day 1; 5-FU 4g/m2 for 5 days continuous infusion from Day 1 to Day 5.

Based on this trial design, predict the completion outcome and termination type (if applicable).